{"schema_version":"secwatch.filing_event.v1","accession":"0001156039-23-000082","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.067108+00:00","generated_at":"2026-06-14T01:50:32.793211+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Elevance Health reaffirms FY2023 adjusted EPS guidance >$32.70","bullets":["Net income guidance >$29.50 per share including ~$3.20 net unfavorable items.","Adjusted net income guidance >$32.70 per share, excluding items from Q1 2023 earnings.","Company officers to meet with investors over upcoming weeks; reaffirms prior outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001156039-23-000082","json":"https://secwatch.observer/filing/0001156039-23-000082.json","markdown":"https://secwatch.observer/filing/0001156039-23-000082.md","text":"https://secwatch.observer/filing/0001156039-23-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000115603923000082/0001156039-23-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000115603923000082/elv-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:50:32.793211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}